Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Org 25935 for relapse prevention in alcohol dependence
NL-OMON33955Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol dependence comparing Org 25935 with Placebo (2 arms). Primary endpoint: Percentage of days of relapse into heavy drinking. Planned start Mar 2009; status: withdrawn.
02
Drugs
org 25935
03
Conditions
alcohol dependence
Beyond the preview
Go deeper on NL-OMON33955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33955.